New Directions in Affective Disorders

Front Matter....Pages i-xlii
Front Matter....Pages 1-1
Neurochemical and Behavioral Effects of Stress: A Rat Model of Depression....Pages 5-8
Study of Olfactory Bulbectomized Rats: Revelations About Major Depressive Disorder....Pages 9-12
Bilaterally Olfactory Bulbectomized Rat Model of Depression....Pages 13-16
Behavioral Despair: Past and Future....Pages 17-20
Genetically Nervous and Normal Pointer Dogs: Relation Between Hearing and Behavioral Abnormalities....Pages 21-24
Agonist-Induced Down-Regulation of β 1 -Adrenergic Receptors: Possible Biochemical Rationale for Novel Antidepressants....Pages 25-28
Behavioral Pharmacology and Clinical Antidepressant Effects of β-Adrenergic Agonists....Pages 29-32
Beyond Nosology in Biological Psychiatry: Prolegomena of a Functional Psychopathology....Pages 35-39
Serotonergic Aspects of Agonistic Behavior....Pages 40-44
Noradrenergic and Serotonergic Dysfunction in the Affective Disorders....Pages 45-48
Neuropeptides and Affective Disorders....Pages 49-53
Antemortem and Postmortem Measures of Central Nervous System Serotonergic Function: Methodological Issues....Pages 54-59
Postmortem Investigation of Serotonergic and Peptidergic Hypotheses of Affective Illness....Pages 60-63
Genetic Animal Model of Depression with Cholinergic Supersensitivity....Pages 67-70
Impact of the Cholinergic System on the Hypothalamic-Pituitary-Adrenocortical Axis and on REM Sleep....Pages 71-74
Relation Between m -Cholinoceptor Density on Human Blood Cells and Psychological Predisposition Factors for Depression....Pages 75-78
Differential Effects of Physostigmine in Alcoholics, Alcoholics with Affective Disorder, and Normal Individuals....Pages 79-81
Serotonin/Norepinephrine/Steroid Receptor Link in Brain and the Mode of Action of Antidepressants: Update and New Perspectives....Pages 85-88
Presynaptic Sites of Antidepressant Action: Monoamine Transport Systems and Release-Modulating Autoreceptors....Pages 89-92
Light-Dark-Related Changes in the Serotonin Uptake Molecular Complex in Rat Brain: Involvement in Antidepressant Action....Pages 93-96
Front Matter....Pages 1-1
Role of Serotonin (and Coexisting Peptides) in the Action Mechanism of Antidepressant Drugs....Pages 97-99
GABA B Receptors and Antidepressant Drugs....Pages 100-103
Antidepressants and Phospholipid Metabolism: β-Adrenoceptor Regulation in Cultured Human Cells....Pages 104-108
Nicotinic Effects of Antidepressants....Pages 109-112
Molecular Sites of Anxiolytic Action....Pages 113-117
Modulation of the Benzodiazepine/GABA Receptor Chloride Ionophore Complex: Evidence for an Asymmetrical Response of GABA-Gated Chloride Channels to Stress....Pages 118-120
Lithium Inhibition of Adenylate Cyclase Activity: Site of Action and Interaction with Divalent Cations....Pages 123-125
Comparison of the Effects of Lithium and Antidepressant Drugs on Second Messenger Systems in Rat Brain....Pages 126-129
Effects of Lithium Ions on the Metabolism of Phosphoinositides....Pages 130-133
Comparison of Theories of Lithium Action Based on Phosphatidylinositol Metabolism with Theories Based on Cyclic AMP....Pages 134-137
Serotonin and Catecholamines in Lithium Treatment....Pages 138-141
Lithium and Calcium Antagonists: Do They Act on One Neuronal Function?....Pages 142-144
Red Blood Cell Lithium Transport in Affective Illness: A Possible Mechanism of Action of Lithium....Pages 145-149
Selective Localization and Selective Inhibition of Monoamine Oxidase in Human Brain....Pages 153-155
Effect of Selective Monoamine Oxidase Substrates and Inhibitors on Lipid Peroxidation and Their Possible Involvement in Affective Disorders....Pages 156-160
Pharmacology of Monoamine Oxidase Inhibitors....Pages 161-163
Regulation of Functional Cytoplasmic Pool of Serotonin by MAO-A and MAO-B: Implications for Antidepressant Therapy....Pages 164-167
Neurochemical Profile of the Antidepressant Moclobemide, a Reversible Type A Monoamine Oxidase Inhibitor with Minimal Tyramine Potentiating Activity in Rats....Pages 168-171
Front Matter....Pages 173-173
Power of Genetic Linkage Studies for Heterogeneous Disorders....Pages 177-180
Single Locus Markers in Affective Disorders....Pages 181-183
Front Matter....Pages 173-173
One Form of Bipolar Affective Disorder is Mapped to Chromosome 11....Pages 184-187
X-Linkage Studies in Affective Disorders....Pages 188-191
Recombinant DNA Studies of X Linkage in Affective Disorders....Pages 192-195
Segregation Analysis in Families of Affective Patients Subdivided According to Treatment Outcome and Personality Disorders....Pages 196-199
Peripheral Blood Cell Biological Markers in Depression....Pages 203-208
α 2 -Adrenoceptors and Associated Functional Responses in Endogenous Depression....Pages 209-212
Neurotransmitters and Their Metabolites in CSF in Depression and Under the Influence of Antidepressant Drugs....Pages 213-216
High Affinity Imipramine Binding and Serotonin Uptake in Human Platelets as a Peripheral Biological Marker in Neuropsychiatric Disorders....Pages 217-220
Resting EEG as a Genetic Marker....Pages 221-224
EEG Sleep Changes in Recurrent Depression....Pages 225-228
Circadian and Ultradian Rhythms of 3-Methoxy-4-Hydroxyphenylglycol in Subtypes of Depressive Illness....Pages 231-235
Chronobiological Dysregulation of the Noradrenergic System in Depression....Pages 236-238
Diurnal Rhythm of Cortisol in Depression: What Is Normal and What Is Not....Pages 239-242
Circadian Rhythm Disturbances in Affective Disorders: Facts and Fictions....Pages 243-250
Pathophysiology of the Limbic-Hypothalamic-Pituitary-Adrenocortex System: An Overview....Pages 253-257
Neuroendocrine Dysfunctions in Affective Disorders: Effects of Clinical Changes....Pages 258-261
Preclinical and Clinical Investigations of Corticotropin-Releasing Factor: Assessment of Its Role in Depressive Disorders....Pages 262-266
Neuroendocrine Effects of Intravenous Ovine Corticotropin-Releasing Factor and Human Growth Hormone-Releasing Factor in Affective Disorder Patients and Normal Controls....Pages 267-271
TRH Stimulation Test in Psychiatry....Pages 272-275
Luteinizing Hormone and Prolactin Response to Buprenorphine in Depression and Schizophrenia....Pages 276-279
Front Matter....Pages 173-173
Neuroendocrine Factors in Antidepressant Drug Therapy....Pages 280-283
Neuroendocrine Studies of the Mechanism of Action of Antidepressant Drugs....Pages 284-286
Growth Hormone Response to Clonidine Stimulation in Affective Disorders: Effects of Lithium Therapy....Pages 287-291
Endocrinological Diseases Mimicking Affective Disorders....Pages 292-296
Front Matter....Pages 297-297
Epidemiology and Psychosocial Risk Factors for Suicide....Pages 301-303
Genetics and Suicidal Behavior in the Affective Disorders....Pages 304-307
Suicidal Behavior Among Children and Adolescents....Pages 308-311
Death Anxiety in a Psychiatric Population of Suicidal and Nonsuicidal Adolescents....Pages 312-316
Neurotransmitters and Neurotransmitter Receptors in Depressed Suicide Victims....Pages 317-319
Peripheral Serotonin and Catecholamine Levels and Suicidal Behavior....Pages 320-325
Past Suicide Attempt and Monoamine Metabolites: Comparing CSF Concentrations and Angularized Ratios....Pages 326-329
Affective Disorders During Childhood and Adolescence: Introduction....Pages 333-334
Study and Treatment of Childhood Depression as a Prototype for the Research and Conceptualization of Other Psychopathologies in Child Psychiatry....Pages 335-339
New Hypotheses of the Pharmacotherapy of Childhood and Adolescent Depression....Pages 340-342
Depression in Children: Defining the Therapeutic Range for Imipramine....Pages 343-346
Good Results with the Dexamethasone Suppression Test in Adolescent Inpatients: Implications for Diagnosis in Adolescent Psychiatry....Pages 347-351
Social Development of Children at High Risk for Depression: Preadolescence and Early Adolescence....Pages 352-355
Psychiatric Disorders in Children of Depressed Parents....Pages 356-359
Diagnostic Criteria for Depression in Alzheimer’s Disease....Pages 363-366
Association of Somatic Disease with Affective Disorders in Middle and Old Age....Pages 367-372
Front Matter....Pages 297-297
Excess Mortality in Late Life Depression....Pages 373-376
Adverse Effects of Antidepressant Drugs in the Elderly....Pages 377-380
Menarche and Menstrual Symptoms: Psychosocial Perspectives....Pages 383-387
Affect and Nurturance in First-Time Mothers: Role of Psychobiological Influences....Pages 388-392
Myth of Menopausal Depression....Pages 393-396
Front Matter....Pages 397-397
Epinephrine-Induced Anxiety and Regional Cerebral Blood Flow in Anxious Patients....Pages 401-403
Neurobiological Mechanisms of Panic Anxiety: Review of the Behavioral, Biochemical, and Cardiovascular Effects of Three Panicogenic Stimuli....Pages 404-409
Caffeine Model of Panic....Pages 410-413
Pharmacological Treatment of Panic Disorders....Pages 414-419
Heterogeneity and Coexistence in DSM-III-R Obsessive Compulsive Disorder....Pages 423-427
Applicability of Models of Anxiety to Obsessive Compulsive Disorder....Pages 428-431
Frontal Lobe Involvement in Obsessive Compulsive Disorder: Electroencephalographic Evidence....Pages 432-434
Pharmacological Treatment of Obsessive Compulsive Disorder....Pages 435-437
Use of Antiandrogens in the Treatment of Obsessive Compulsive Disorders: Theoretical Considerations....Pages 438-440
Psychobiology of the Trauma Response....Pages 443-446
Psychophysiology of Posttraumatic Stress Disorder....Pages 447-450
From CSR to PTSD....Pages 451-454
Social Support Versus Self-Sufficiency in Traumatic and Posttraumatic Stress Reactions....Pages 455-458
Pharmacotherapy Trials in Posttraumatic Stress Disorder: Prospects and Problems....Pages 459-462
Psychobiology of Dissociation....Pages 463-465
Front Matter....Pages 397-397
Eating Disorder and Affective Disorder: How Real Is the Relation?....Pages 469-474
Neuroendocrine Findings in Depression, Anorexia Nervosa, and Bulimia....Pages 475-479
Antidepressant Therapies for Treatment of Anorexia Nervosa and Bulimia Nervosa....Pages 480-483
Psychodynamic Reflections on Anorexia Nervosa....Pages 484-488
Schizoaffective Psychoses: Six Hypotheses....Pages 491-494
Psychopharmacology of Schizoaffective Mania....Pages 495-500
Neuroendocrinology of Schizoaffective Disorders....Pages 501-504
Prophylaxis of Schizoaffective Disorders....Pages 505-508
Treatment of Depression in Schizophrenia....Pages 509-512
Front Matter....Pages 513-513
Pharmacotherapy and the Overlap Between Affective and Other Psychiatric Disorders....Pages 517-520
Classification of Affective Disorders and Psychopharmacology: Rosetta Stone or Hypothetical Construct?....Pages 521-524
Diagnostic Dimensions of the Newcastle Scales and the Response to Antidepressant Treatments....Pages 525-527
Mode of Action of Anticonvulsants in Affective Illness....Pages 531-534
Acute and Prophylactic Properties of Carbamazepine in Bipolar Affective Disorders....Pages 535-539
Use of Carbamazepine in Affective Illness....Pages 540-544
Action of Carbamazepine Suspension in Acute Manic Syndromes....Pages 545-548
Carbamazepine in the Long-Term Treatment of Affective Disorders: Research Strategies....Pages 549-552
Plasma Levels of Carbamazepine in Affective Disorder....Pages 553-556
Efficacy and Safety of Lithium-Carbamazepine Combination in Mania....Pages 557-559
Patient Characteristics and Factors Associated with Chronic Depression and Its Treatment....Pages 563-567
Front Matter....Pages 513-513
Clinical Characteristics of Placebo Response in Depression....Pages 587-591
Pretreatment Pituitary-Adrenocortical Status: Prediction of Placebo Response in Depression....Pages 592-595
Clinical Features, DST, and Response to Placebo in Depressed Outpatients....Pages 596-601
Resistant Depression: Clinical Characteristics and Response to Treatment....Pages 568-572
Clinical Indicators in Resistant Depressions....Pages 573-576
Combined MAO Inhibitor and Tri/Tetracyclic Antidepressant Treatment in Therapy-Resistant Depression....Pages 577-581
Management of Resistant Major Depression....Pages 582-584
GABA Theory of Depression and Antidepressant Drug Action....Pages 651-654
GABA-Mimetic Agent Fengabine in the Treatment of Depression: An Overview....Pages 655-659
Antidepressant Activity of Progabide and Fengabine....Pages 660-664
Activity of Fengabine, a GABAergic Drug, in Depression....Pages 665-668
Antidepressant Drug Measurement: Review of Methods for Clinical Application....Pages 605-610
Relation Between Plasma Antidepressant Concentrations and Clinical Effects....Pages 611-615
Clinical Implications of the Tricyclic Antidepressant Hydroxy-Metabolites....Pages 616-619
Disposition and Effects of E-10-Hydroxynortriptyline—An Active Metabolite of Nortriptyline....Pages 620-622
Genetic Polymorphism in Drug Oxidation: Implications for the Clinical Use of Tricyclic Antidepressants....Pages 623-627
Overdosage of Antidepressants....Pages 631-634
Risk-Benefit Assessment of Deaths from Adverse Drug Reactions and Overdosage with Antidepressants....Pages 635-637
Assessing the Safety of Antidepressant Drugs After Marketing: A U.S. View....Pages 638-642
Tricyclic Antidepressants, Electroconvulsive Therapy, and Memory in Depressed Patients....Pages 643-647
Front Matter....Pages 513-513
Depression in Children and Adolescents: A Controlled Study of Progabide Versus Imipramine....Pages 669-673
Electrode Placement and Stimulus Waveform: Conceptual and Practical Issues....Pages 677-680
Unilateral and Bilateral Electroconvulsive Therapy in Depressive Illness....Pages 681-684
ECT: Rising Trends and Current Policy....Pages 685-688
Pharmacological Manipulation of Seizure Duration: A New Direction in ECT Technology....Pages 689-691
“Isoflurane Narcotherapy” in Depression: Methodological Issues....Pages 692-695
Response to Combined Pharmacotherapy and Psychotherapy Among Recurrent Depressives....Pages 699-702
Cognitive Therapy for Major Depressive Disorder: Current Status....Pages 703-706
Use of Reminiscing in the Psychotherapy of Depression....Pages 707-709
Back Matter....Pages 711-732